David Scott Jones - 22 Jan 2024 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
SVP & Chief Commercial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
22 Jan 2024
Net transactions value
-$435,042
Form type
4
Filing time
24 Jan 2024, 16:50:28 UTC
Previous filing
09 Jan 2024
Next filing
26 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $291,238 +28,750 +76% $10.13 66,712 22 Jan 2024 Direct
transaction EYPT Common Stock Options Exercise $62,122 +5,416 +8.1% $11.47 72,128 22 Jan 2024 Direct
transaction EYPT Common Stock Sale $120,437 -5,416 -7.5% $22.24 66,712 22 Jan 2024 Direct F1
transaction EYPT Common Stock Sale $652,254 -28,750 -43% $22.69 37,962 22 Jan 2024 Direct F2
transaction EYPT Common Stock Options Exercise $5,160 +400 +1.1% $12.90 38,362 23 Jan 2024 Direct
transaction EYPT Common Stock Options Exercise $1,630 +500 +1.3% $3.26 38,862 23 Jan 2024 Direct
transaction EYPT Common Stock Sale $10,000 -400 -1% $25.00 38,462 23 Jan 2024 Direct
transaction EYPT Common Stock Sale $12,500 -500 -1.3% $25.00 37,962 23 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -5,416 -54% $0.000000 4,584 22 Jan 2024 Common Stock 5,416 $11.47 Direct F3
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -28,750 -48% $0.000000 31,250 22 Jan 2024 Common Stock 28,750 $10.13 Direct F4
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -400 -1.6% $0.000000 24,225 23 Jan 2024 Common Stock 400 $12.90 Direct F5
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -500 -0.55% $0.000000 91,155 23 Jan 2024 Common Stock 500 $3.26 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.04. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The option to purchase will vest and become exercisable as follows: 25% at November 1st, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.
F4 The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.
F5 The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
F6 The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.